ANTI-IL-13 ANTIBODY FORMULATION; Aerosol FORMULATION OF ANTI-IL-13 ANTIBODY; Lyophilized FORMULATION OF ANTI-IL-13 ANTIBODY; PHARMACEUTICAL COMPOSITION FOR TREATMENT OF IL-13-RELATED DISORDER; MANUFACTURE OF A PHARMACEUTICAL COMPOSITION; METHOD OF TREATMENT OF IL-13-RELATED DISORDER; INJECTABLE SYRINGE; NASAL ADMINISTRATION DEVICE; Transdermal patch; INTRAVENOUS PURSE; KIT UNDERSTANDING AT LEAST ONE CONTAINER; KIT; AND PREJECTED INJECTABLE SYRINGE

摘要

FORMULATION OF ANTI-IL-13 ANTIBODY; AEROSOL FORMULATION OF ANTI-IL-13 ANTIBODY; Lyophilized EORMULATION OF ANTI-IL-13 ANTIBODY; PHARMACEUTICAL COMPOSITION FOR TREATMENT OF IL-13-RELATED DISORDER; MANUFACTURE OF A PHARMACEUTICAL COMPOSITION; METHOD OF TREATMENT OF IL-13-RELATED DISORDER; INJECTABLE SYRINGE; NASAL ADMINISTRATION DEVICE; TRANSDERMAL PLASTER; INTRAVENOUS PURSE; KIT UNDERSTANDING AT LEAST ONE CONTAINER; KIT; AND PREJECTED INJECTABLE SYRINGE. Suitable formulations are presented for the treatment of disorders associated with IL-13 undesirable expression or activity.